Haematologica, Vol 92, Issue 10, 1351-1358 doi:10.3324/haematol.11325
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kastritis, E.
Right arrow Articles by Dimopoulos, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kastritis, E.
Right arrow Articles by Dimopoulos, M. A.
Related Collections
Right arrowRelated Article

Amyloidosis

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

Efstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, Savvas Toumanidis, Constantinos Pamboukas, Magdalini Migkou, Anna Tassidou, Irini Xilouri, Sossana Delibasi, Erasmia Psimenou, Sofia Mellou, Evangelos Terpos, John Nanas, Meletios A. Dimopoulos

From the Department of Clinical Therapeutics, Alexandra Hospital, University of Athens, School of Medicine, Athens, Greece (EK, AA, MR, ST, CP, MM, EP, JN, MAD); Department of Hemopathology, Evangelismos Hospital, Athens, Greece (AT); Department of Hematology, University Hospital of Heraklion, Crete, Greece (IX); Department of Hematology, Evangelismos Hospital, Athens, Greece (SD); Henry Dynan Hospital, Athens, Greece (SM); General Airforce Hospital, Athens, Greece (ET)

Correspondence: Meletios A. Dimopoulos, M.D., 227 Kifissias Avenue, Kifissia, Athens 14561, Greece. E-mail: mdimop{at}med.uoa.gr

Background and Objectives: High-dose melphalan and autologous stem cell transplantation is currently the treatment of choice for selected patients with AL amyloidosis; however, new treatments are needed for patients who are ineligible for or relapse after this procedure. Bortezomib is a proteasome inhibitor with proven activity in multiple myeloma, and the addition of dexamethasone results in superior outcome. We evaluated the activity and feasibility of the combination of bortezomib and dexamethasone (BD) in patients with AL amyloidosis.

Design and Methods: Consecutive patients with histologically proven, symptomatic AL amyloidosis were treated with BD.

Results: Eighteen patients, including seven who had relapsed or progressed after previous therapies were treated with BD. Eleven (61%) patients had two or more organs involved; kidneys and heart were affected in 14 and 15 patients, respectively. The majority of patients had impaired performance status and high brain natriuretic peptide values; serum creatinine was elevated in six patients. Among evaluable patients, 94% had a hematologic response and 44% a hematologic complete response, including all five patients who had not responded to prior high dose dexamethasone-based treatment and one patient under dialysis. Five patients (28%) had a response in at least one affected organ. Hematologic responses were rapid (median 0.9 months) and median time to organ response was 4 months. Neurotoxicity, fatigue, peripheral edema, constipation and exacerbation of postural hypotension were manageable although necessitated dose adjustment or treatment discontinuation in 11 patients.

Interpretation and Conclusions: The combination of BD is feasible in patients with AL amyloidosis. Patients achieve a rapid hematologic response and toxicity can be managed with close follow-up and appropriate dose adjustment. This treatment may be a valid option for patients with severe heart or kidney impairment.

Key words: primary amyloidosis, bortezomib, BNP, renal failure.


Related Article

Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Roberto Sitia, Giovanni Palladini, Giampaolo Merlini
Haematologica 2007 92: 1302-1307. [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
R. L. Comenzo
How I treat amyloidosis
Blood, October 8, 2009; 114(15): 3147 - 3157.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. A. Gertz, N. Leung, M. Q. Lacy, A. Dispenzieri, S. R. Zeldenrust, S. R. Hayman, F. K. Buadi, D. Dingli, P. R. Greipp, S. K. Kumar, et al.
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3132 - 3137.
[Abstract] [Full Text] [PDF]


Home page
BMJ Case ReportsHome page
K. Karthikeyan, N. Jagjivan, M. Lyttelton, and J. Cullen
Cardiac amyloidosis: can advances in diagnostics and treatments improve survival?
BMJ Case Reports, August 17, 2009; 2009(aug17_1): bcr0120091469 - bcr0120091469.
[Abstract] [Full Text]


Home page
haematolHome page
G. Palladini and G. Merlini
Current treatment of AL amyloidosis
Haematologica, August 1, 2009; 94(8): 1044 - 1048.
[Full Text] [PDF]


Home page
haematolHome page
I. I. van Gameren, M. H. van Rijswijk, J. Bijzet, E. Vellenga, and B. P. Hazenberg
Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain
Haematologica, August 1, 2009; 94(8): 1094 - 1100.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. M. Dember
Modern Treatment of Amyloidosis: Unresolved Questions
J. Am. Soc. Nephrol., March 1, 2009; 20(3): 469 - 472.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
S. O. Schonland, N. Kroger, C. Wolschke, P. Dreger, A. D. Ho, and U. Hegenbart
Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect"
Haematologica, March 1, 2009; 94(3): 439 - 441.
[Full Text] [PDF]


Home page
BloodHome page
A. Solomon, S. D. Macy, C. Wooliver, D. T. Weiss, and P. Westermark
Splenic plasma cells can serve as a source of amyloidogenic light chains
Blood, February 12, 2009; 113(7): 1501 - 1503.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
E. Kastritis, M. Migkou, M. Gavriatopoulou, P. Zirogiannis, V. Hadjikonstantinou, and M. A. Dimopoulos
Treatment of light chain deposition disease with bortezomib and dexamethasone
Haematologica, February 1, 2009; 94(2): 300 - 302.
[Full Text] [PDF]


Home page
haematolHome page
R. Sitia, G. Palladini, and G. Merlini
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Haematologica, October 1, 2007; 92(10): 1302 - 1307.
[Full Text] [PDF]